|
US3133858A
(en)
*
|
1954-03-24 |
1964-05-19 |
Abbott Lab |
Stable thiobarbituric acid solution
|
|
CH527207A
(de)
|
1968-05-08 |
1972-08-31 |
Ceskoslovenska Akademie Ved |
Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
|
|
DE2105468A1
(en)
|
1970-04-23 |
1971-11-18 |
Czeskoslovenska akademie ved, Prag; VtnKarstedt, E., Dipl.-Ing. Dr., Pat-Anw., 4200 Oberhausen |
1-glycosyl-5-aza-cytosines prepn
|
|
US5157120A
(en)
|
1980-09-16 |
1992-10-20 |
Syntex (U.S.A.) Inc. |
Guanine derivatives
|
|
US4855304A
(en)
|
1985-01-10 |
1989-08-08 |
Repligen Corporation |
Dinucleoside pyrophosphates and pyrophosphate homologs as plant antivirals
|
|
JPS61176523A
(ja)
|
1985-01-30 |
1986-08-08 |
Teruhiko Beppu |
制癌剤
|
|
GB8612826D0
(en)
|
1986-05-27 |
1986-07-02 |
Boots Co Plc |
Insecticidal compositions
|
|
DE3712786A1
(de)
|
1987-04-15 |
1988-11-03 |
Merck Patent Gmbh |
Verfahren und mittel zur bestimmung von nucleinsaeuren
|
|
CS269077B1
(cs)
|
1987-10-01 |
1990-04-11 |
Piskala Alois |
Způsob přípravy 5-azacytosinů
|
|
US5968914A
(en)
|
1987-10-28 |
1999-10-19 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
US5736531A
(en)
|
1987-10-28 |
1998-04-07 |
Pro-Neuron, Inc. |
Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
|
|
US4904770A
(en)
|
1988-03-24 |
1990-02-27 |
Bristol-Myers Company |
Production of 2',3'-dideoxy-2',3'-didehydronucleosides
|
|
US5324831A
(en)
|
1988-04-06 |
1994-06-28 |
The United States Of America As Represented By The Secretary Of Health And Human Services |
Phosphoramidite reagent for chemical synthesis of modified DNA
|
|
PT93772A
(pt)
|
1989-04-17 |
1991-01-08 |
Searle & Co |
Processo para a preparacao de composicoes para o tratamento de neoplasias, contendo um agente anti-neoplastico, por exemplo doxorubicina e um agente protector para reduzir os efeitos secundarios, por exemplo carbetimer
|
|
ZA923640B
(en)
|
1991-05-21 |
1993-02-24 |
Iaf Biochem Int |
Processes for the diastereoselective synthesis of nucleosides
|
|
CA2111571C
(en)
|
1991-07-05 |
2005-08-23 |
Reid W. Von Borstel |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
IL103311A0
(en)
|
1991-10-07 |
1993-03-15 |
Univ Johns Hopkins |
Formation of triple helix complexes of single stranded nucleic acids using nucleoside oligomers
|
|
JPH05219974A
(ja)
|
1992-02-13 |
1993-08-31 |
Mitsui Petrochem Ind Ltd |
トロパンアルカロイドの製造方法
|
|
JPH05246891A
(ja)
*
|
1992-03-09 |
1993-09-24 |
Kobayashi Seiyaku Kogyo Kk |
安定な抗膵炎用注射液
|
|
US5607691A
(en)
|
1992-06-12 |
1997-03-04 |
Affymax Technologies N.V. |
Compositions and methods for enhanced drug delivery
|
|
WO1994026761A1
(en)
|
1993-05-14 |
1994-11-24 |
Pro-Neuron, Inc. |
Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
|
|
GB9311252D0
(en)
|
1993-06-01 |
1993-07-21 |
Hafslund Nycomed As |
Cell growth regualtors
|
|
WO1995015373A2
(en)
|
1993-11-30 |
1995-06-08 |
Mcgill University |
Inhibition of dna methyltransferase
|
|
US6432924B1
(en)
|
1993-12-26 |
2002-08-13 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
US5856090A
(en)
|
1994-09-09 |
1999-01-05 |
The Scripps Research Institute |
DNA-methylase linking reaction
|
|
US20030104576A1
(en)
|
1994-10-07 |
2003-06-05 |
Jonathan W. Nyce |
Dna construct, composition, formulations & methods for making the construct & for modulating expression
|
|
JPH11505422A
(ja)
|
1995-05-19 |
1999-05-21 |
フィテラ インク． |
植物細胞培養物および植物組織培養物の処理方法
|
|
AU706026B2
(en)
|
1995-06-06 |
1999-06-10 |
Case Western Reserve University |
Myogenic differentiation of human mesenchymal stem cells
|
|
CA2241255A1
(en)
|
1995-12-22 |
1997-07-03 |
East Carolina University |
Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
|
|
CA2267279A1
(en)
|
1996-10-16 |
1998-04-23 |
Devron Averett |
Monocyclic l-nucleosides, analogs and uses thereof
|
|
US6423692B2
(en)
|
1997-04-24 |
2002-07-23 |
Dana-Farber Cancer Institute, Inc. |
Method of enhancing the effectiveness of DCK phosphorylated molecules
|
|
US6153383A
(en)
|
1997-12-09 |
2000-11-28 |
Verdine; Gregory L. |
Synthetic transcriptional modulators and uses thereof
|
|
SI1053325T1
(sl)
|
1998-02-05 |
2006-06-30 |
Glaxosmithkline Biolog Sa |
S tumorjem povezani antigenski derivati iz MAGE druzine in sekvence nukleinske kisline, ki jih kodirajo, uporabljeni za pripravo fuzijskih proteinov in sestavkov za vakcinacijo
|
|
JP2002528391A
(ja)
|
1998-10-19 |
2002-09-03 |
メチルジェン，インク． |
組合せ治療による遺伝子発現の修飾
|
|
AU772676B2
(en)
|
1998-12-23 |
2004-05-06 |
Amgen Fremont Inc. |
Human monoclonal antibodies to CTLA-4
|
|
WO2000040269A2
(en)
|
1999-01-05 |
2000-07-13 |
Lee Clarence C |
Pharmaceutical compositions for treatment of diseased tissues
|
|
WO2000062075A1
(en)
|
1999-04-13 |
2000-10-19 |
Rutgers, The State University Of New Jersey |
Ubiquitin cross-reactive protein as a prognostic marker for tumor cell chemosensitivity
|
|
CA2377385A1
(en)
|
1999-06-03 |
2000-12-14 |
Jessie L.S. Au |
Methods and compositions for modulating cell proliferation and cell death
|
|
DE19935303A1
(de)
|
1999-07-28 |
2001-02-08 |
Aventis Pharma Gmbh |
Oligonukleotide zur Inhibierung der Expression von humanem eg5
|
|
AU784012B2
(en)
|
1999-08-24 |
2006-01-12 |
E. R. Squibb & Sons, L.L.C. |
Human CTLA-4 antibodies and their uses
|
|
JP2001163776A
(ja)
*
|
1999-09-30 |
2001-06-19 |
Nisshin Oil Mills Ltd:The |
安定化された液剤
|
|
AU785115B2
(en)
|
1999-10-18 |
2006-09-21 |
Emory University |
TMS1 compositions and methods of use
|
|
US20020115117A1
(en)
|
2000-03-15 |
2002-08-22 |
Shuk-Mei Ho |
ERbeta-mediated gene expression
|
|
US7001769B2
(en)
|
2000-09-08 |
2006-02-21 |
Seoul National University Industry Foundation |
Nucleic acid sequences and proteins involved in cellular senescence
|
|
US6919370B2
(en)
*
|
2000-11-28 |
2005-07-19 |
Transform Pharmaceuticals, Inc. |
Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
|
|
WO2002053138A2
(en)
|
2001-01-02 |
2002-07-11 |
Elisabeth Shanahan-Prendergast |
Treatment for inhibiting neoplastic lesions using incensole and/or furanogermacrens
|
|
JP2004532184A
(ja)
|
2001-01-22 |
2004-10-21 |
メルク エンド カムパニー インコーポレーテッド |
Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害薬としてのヌクレオシド誘導体
|
|
JP2002223753A
(ja)
|
2001-01-30 |
2002-08-13 |
Hitachi Ltd |
薬物応答解析用オリゴヌクレオチドアレイ
|
|
JP2004527242A
(ja)
|
2001-02-05 |
2004-09-09 |
イノベンタス プロジェクト アクチボラゲット |
ヒスチジンリッチ糖タンパク質
|
|
US6613753B2
(en)
|
2001-02-21 |
2003-09-02 |
Supergen, Inc. |
Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
|
|
AU2002252183A1
(en)
|
2001-03-06 |
2002-09-19 |
Biocryst Pharmaceuticals, Inc. |
Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
|
|
US20060194275A1
(en)
|
2001-04-13 |
2006-08-31 |
Incyte Corporation |
Transporter and ion channels
|
|
US6905669B2
(en)
|
2001-04-24 |
2005-06-14 |
Supergen, Inc. |
Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
|
|
WO2002087586A1
(en)
|
2001-04-26 |
2002-11-07 |
Control Delivery Systems, Inc. |
Sustained release drug delivery system containing codrugs
|
|
US20030148973A1
(en)
|
2001-05-23 |
2003-08-07 |
Peter Emtage |
MAGE-A1 peptides for treating or preventing cancer
|
|
EP1402071A4
(en)
|
2001-06-08 |
2005-12-14 |
Us Genomics Inc |
METHOD AND PRODUCTS FOR THE ANALYSIS OF NUCLEIC ACIDS BASED ON THE METHYLATION STATUS
|
|
JP2002370939A
(ja)
|
2001-06-12 |
2002-12-24 |
Taisho Pharmaceut Co Ltd |
育毛剤
|
|
SE0102627L
(sv)
|
2001-07-27 |
2002-11-19 |
Geneinvent Bbl Ab |
Vektorer motståndskraftiga mot metylering
|
|
US20030045497A1
(en)
|
2001-07-27 |
2003-03-06 |
Geneinvent Bbl Ab |
Methylation resistant vectors
|
|
WO2003012085A1
(en)
|
2001-07-30 |
2003-02-13 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Antigen presenting cells, method for their preparation and their use for cancer vaccines
|
|
ES2383771T3
(es)
|
2001-09-05 |
2012-06-26 |
IVAX International GmbH |
Homoharringtonina sola o combinada con otros agentes para su utilización en el tratamiento de la leucemia mielógena crónica resistente o intolerante a los inhibidores de la proteína cinasa diferentes al STI571
|
|
IN2014DN10834A
(enExample)
|
2001-09-17 |
2015-09-04 |
Psivida Inc |
|
|
US20030158598A1
(en)
|
2001-09-17 |
2003-08-21 |
Control Delivery Systems, Inc. |
System for sustained-release delivery of anti-inflammatory agents from a coated medical device
|
|
JP2005508322A
(ja)
|
2001-09-24 |
2005-03-31 |
ジェシー エル エス オウ |
併用療法に用いられるスラミンの化学増感用量を決定するための方法及び成分
|
|
US7432050B2
(en)
|
2001-10-05 |
2008-10-07 |
Case Western Reserve University |
Methods and compositions for detecting colon cancers
|
|
CN1323163C
(zh)
|
2001-11-08 |
2007-06-27 |
独立行政法人科学技术振兴机构 |
水稻转座子基因
|
|
JP2005514359A
(ja)
|
2001-11-23 |
2005-05-19 |
中外製薬株式会社 |
腫瘍を標的とする酵素の同定法
|
|
AU2002365291B2
(en)
|
2001-11-29 |
2007-11-01 |
Dandrit Biotech A/S |
Pharmaceutical composition for inducing an immune response in a human or animal
|
|
EP1448782A1
(de)
|
2001-11-30 |
2004-08-25 |
MediGene Aktiengesellschaft |
Optimierte herstellung von viralen, von parvoviren abgeleiteten vektoren in verpackungs- und produktionszellen durch hsv-infektion oder behandlung mit inhibitoren der dna-methylierung
|
|
GB0201498D0
(en)
|
2002-01-23 |
2002-03-13 |
Biotech Res Ventures Pte Ltd |
Materials and methods for treating cancer
|
|
US20030147813A1
(en)
|
2002-02-07 |
2003-08-07 |
John Lyons |
Method for treating chronic myelogenous leukemia
|
|
US6998391B2
(en)
|
2002-02-07 |
2006-02-14 |
Supergen.Inc. |
Method for treating diseases associated with abnormal kinase activity
|
|
EP1483401A1
(en)
|
2002-03-13 |
2004-12-08 |
F.Hoffmann-La Roche Ag |
Method for selecting drug sensitivity-determining factors and method for predicting drug sensitivity using the selected factors
|
|
JP2003310293A
(ja)
|
2002-04-26 |
2003-11-05 |
Mitsui Chemicals Inc |
ヌクレオシド化合物の製造法
|
|
SG165158A1
(en)
|
2002-05-02 |
2010-10-28 |
Wyeth Corp |
Calicheamicin derivative-carrier conjugates
|
|
WO2003104427A2
(en)
|
2002-06-05 |
2003-12-18 |
Case Western Reserve University |
Methods and compositions for detecting cancers
|
|
US6982253B2
(en)
*
|
2002-06-05 |
2006-01-03 |
Supergen, Inc. |
Liquid formulation of decitabine and use of the same
|
|
WO2004041195A2
(en)
|
2002-10-31 |
2004-05-21 |
Supergen, Inc. |
Pharmaceutical formulations targeting specific regions of the gastrointestinal tract
|
|
US20050037992A1
(en)
|
2003-07-22 |
2005-02-17 |
John Lyons |
Composition and method for treating neurological disorders
|
|
US20050059682A1
(en)
|
2003-09-12 |
2005-03-17 |
Supergen, Inc., A Delaware Corporation |
Compositions and methods for treatment of cancer
|
|
WO2005033278A2
(en)
|
2003-09-30 |
2005-04-14 |
Ludwig Institute For Cancer Research |
In vivo efficacy of ny-eso-1 plus iscom
|
|
US7846436B2
(en)
|
2003-11-28 |
2010-12-07 |
Chemgenes Corporation |
Oligonucleotides and related compounds
|
|
ATE422367T1
(de)
|
2004-05-26 |
2009-02-15 |
Biovaxim Ltd |
Zusammensetzungen aus demethylierenden mitteln als verstärker der immuntherapie zur behanldung von chronischen infektionen und neoplastischen erkrankungen und behandlungsverfahren dafür
|
|
US20060014949A1
(en)
*
|
2004-07-13 |
2006-01-19 |
Supergen Inc. |
Compositions and formulations of decitabine polymorphs and methods of use thereof
|
|
US20060063735A1
(en)
|
2004-09-17 |
2006-03-23 |
Supergen, Inc. |
Salts of 5-azacytidine
|
|
US20060069060A1
(en)
|
2004-09-27 |
2006-03-30 |
Sanjeev Redkar |
Salts of decitabine
|
|
CN101052655A
(zh)
|
2004-11-04 |
2007-10-10 |
辉瑞产品有限公司 |
用于治疗乳腺癌的ctla4抗体和芳香酶抑制剂组合物
|
|
US20060128654A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20060128653A1
(en)
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
CA2592968A1
(en)
|
2004-12-29 |
2006-07-06 |
Mannkind Corporation |
Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
|
|
US7250416B2
(en)
|
2005-03-11 |
2007-07-31 |
Supergen, Inc. |
Azacytosine analogs and derivatives
|
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Alternative amide derivatives and methods of use
|
|
JP4361545B2
(ja)
|
2005-05-09 |
2009-11-11 |
小野薬品工業株式会社 |
ＰｒｏｇｒａｍｍｅｄＤｅａｔｈ１（ＰＤ−１）に対するヒトモノクローナル抗体および抗ＰＤ−１抗体単独または他の免疫療法と併用した癌治療方法
|
|
HRP20151102T1
(xx)
|
2005-07-01 |
2015-11-20 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska antitijela za ligand programirane smrti 1 (pd-l1)
|
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
|
US20070105792A1
(en)
|
2005-11-04 |
2007-05-10 |
Dimartino Jorge F |
Administration Of DNA Methylation Inhibitors For Treating Epigenetic Diseases
|
|
US20070117776A1
(en)
|
2005-11-04 |
2007-05-24 |
John Lyons |
Low Dose Therapy Of DNA Methylation Inhibitors
|
|
CN101637444B
(zh)
*
|
2006-03-17 |
2012-08-15 |
山东蓝金生物工程有限公司 |
含吉西他滨的抗癌药物缓释注射剂
|
|
US20090142337A1
(en)
*
|
2006-05-08 |
2009-06-04 |
Astex Therapeutics Limited |
Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
|
|
US8003324B2
(en)
*
|
2007-10-18 |
2011-08-23 |
U.S. Department Of Veterans Affairs |
Modulation of sodium channels by nicotinamide adenine dinucleotide
|
|
CN101570553B
(zh)
*
|
2008-05-04 |
2012-03-28 |
上海医药工业研究院 |
一种2-脱氧-d-核糖的衍生物及其制备方法和用途
|
|
CN101361718B
(zh)
*
|
2008-09-26 |
2013-08-28 |
深圳万乐药业有限公司 |
稳定的地西他滨冻干制剂的制备方法
|
|
CN101787046B
(zh)
*
|
2010-02-11 |
2012-12-26 |
福建南方制药股份有限公司 |
地西他滨的中间体化合物的制备方法
|
|
GB201006096D0
(en)
|
2010-04-13 |
2010-05-26 |
Alligator Bioscience Ab |
Novel compositions and uses thereof
|
|
EP2614086A1
(en)
|
2010-09-08 |
2013-07-17 |
Halozyme, Inc. |
Methods for assessing and identifying or evolving conditionally active therapeutic proteins
|
|
CN101966157B
(zh)
*
|
2010-10-14 |
2013-08-14 |
苏州特瑞药业有限公司 |
一种地西他滨缓释微球及其制备方法
|
|
CN103596974B
(zh)
|
2011-04-15 |
2016-08-31 |
卡姆普根有限公司 |
多肽和多核苷酸及其用于治疗免疫相关失调和癌症的用途
|
|
LT2750768T
(lt)
|
2011-08-30 |
2019-02-11 |
Astex Pharmaceuticals, Inc. |
Decitabino darinio kompozicijos
|
|
WO2013117969A1
(en)
|
2012-02-06 |
2013-08-15 |
Fresenius Kabi Oncology Ltd. |
Process for preparing stable pharmaceutical compositions of compounds susceptible to hydrolysis
|
|
LT2961388T
(lt)
|
2013-03-01 |
2019-08-26 |
Astex Pharmaceuticals, Inc. |
Vaistų deriniai
|
|
JP6768722B2
(ja)
|
2015-07-02 |
2020-10-14 |
大塚製薬株式会社 |
凍結乾燥医薬組成物
|
|
AU2018310857A1
(en)
|
2017-08-03 |
2020-02-13 |
Otsuka Pharmaceutical Co., Ltd. |
Drug compound and purification methods thereof
|